Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3731451 | 0.91 | ALOX5 (0.51) | ALOX5 | |
| SCHEMBL27915428 | 0.82 | ALOX5 (0.43) | ALOX5CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL9259587 | 0.82 | ALOX5 (0.56) | ALOX5SLC6A2SLC6A4 | |
| SCHEMBL31353592 | 0.81 | ALOX5 (0.42) | ALOX5 | |
| SCHEMBL25840164 | 0.79 | ALOX5 (0.44) | ALOX5CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL31543489 | 0.78 | ALOX5 (0.39) | ALOX5SLC6A4 | |
| SCHEMBL9371373 | 0.77 | CHRNA1 (0.38) | ALOX5CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL16203267 | 0.73 | CHRNA1 (0.43) | ALOX5CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL12672077 | 0.73 | ALOX5 (0.52) | ALOX5 | |
| SCHEMBL19330863 | 0.73 | CHRNA1 (0.38) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022083560-A1 | TYK2 SELECTIVE INHIBITOR AND USE THEREOF | 南京药石科技股份有限公司 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | ALOX5 4280/4885CHRNA1 2354/4885CHRNG 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.